News
Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.
Zacks Investment Research on MSN1h
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock TanksShares of Capricor Therapeutics CAPR tanked 33% on Friday after it announced that the FDA issued a complete response letter ( ...
Investor's Business Daily on MSN2h
Kenvue Surges After Tylenol-Maker Announces Sweeping ChangesKenvue stock surged Monday after the company — known for brands like Tylenol — announced sweeping changes, including naming a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback